esc
Search documents
go
Browse entities
go
Corpus stats
go
About the data
go
AI settings
go
EFTA
Search
Search
Entities
About
Stats
Settings
⌘K
search
Search
Search syntax help
Dataset
Set 1
Set 2
Set 3
Set 4
Set 5
Set 6
Set 7
Set 8
Set 9
Set 10
Set 11
Set 12
Sort
Relevance
Most pages
Most words
Dataset
Newest
Oldest
Status
All
Extracted
Failed
DOJ Status
All
Removed
Available
Modified
Date Range
Undated only
–
Email Headers
Page Count
–
Saved Searches
+
45 results for “
"OvationBio"
”
Export
Keyboard Shortcuts
/
Focus search
Esc
Blur input
O
Open PDF
←
→
Paginate
Corpus: 1990-03-17 – 2025-12-01
←
March 2015
→
Mo
Tu
We
Th
Fr
Sa
Su
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Undated
(150,429)
None
Light
Medium
Heavy
EFTA02082969
Dataset 10
2015-03-06
3p
809w
Subject:
RE: Investment Opportunities
From:
David Carter
To:
David Carter
…on a super cost effective basis.
OvationBio
needs to do proof of concept studies, and develop its intellectual property, before it starts to EFTA_R1_00668123 EFTA02082970 raise real money.
OvationBio
needs $1.5M to complete this early work. In olden days this would be something the NIH would fund, but there is no more real NIH money, so I am looking for private investors with a "civic minded interest". (The Russians Love
OvationBio
, but we need to show them…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02082969.pdf
EFTA02083923
Dataset 10
2015-03-06
4p
824w
Subject:
RE: Investment Opportunities
From:
David Carter
To:
David Carter
…00670805 EFTA02083924 and return, to provide
OvationBio
the capital it needs to do its early work. Somehow
OvationBio
is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the biggest medical problems in the world—hospital based infections, i.e. MRSA. In addition,
OvationBio
' s technology could produce human enzymes, in modified chickens, on a super cost effective basis.
OvationBio
needs to do proof of concept studies, and develop its…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02083923.pdf
EFTA02082294
Dataset 10
2015-03-16
3p
937w
Subject:
Re: Investment Opportunities
From:
111.
To:
David Carter
…to risk and return, to provide
OvationBio
the capital it needs to do its early work. Somehow
OvationBio
is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the biggest medical problems in the world—hospital based infections, i.e. MRSA. In addition,
OvationBio
' s technology could produce human enzymes, in modified chickens, on a super cost effective basis.
OvationBio
needs to do proof of concept studies, and develop its…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02082294.pdf
EFTA02082281
Dataset 10
2015-03-16
3p
829w
Subject:
Fwd: Investment Opportunities
From:
"David Carter"
To:
Jeffrey E stein[jeevacation©gmail.com]
…to risk and return, to provide
OvationBio
the capital it needs to do its early work. Somehow
OvationBio
is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the biggest medical problems in the world—hospital based infections, i.e. MRSA. In addition,
OvationBio
' s technology could produce human enzymes, in modified chickens, on a super cost effective basis.
OvationBio
needs to do proof of concept studies, and develop its…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02082281.pdf
EFTA02082320
Dataset 10
2015-03-16
3p
842w
Subject:
Re: Investment Opportunities
From:
David Carter
To:
David Carter
…to risk and return, to provide
OvationBio
the capital it needs to do its early work. Somehow
OvationBio
is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the biggest medical problems in the world—hospital based infections, i.e. MRSA. In addition,
OvationBio
' s technology could produce human enzymes, in modified chickens, on a super cost effective basis.
OvationBio
needs to do proof of concept studies, and develop its…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02082320.pdf
EFTA02082357
Dataset 10
2015-03-05
3p
897w
Subject:
Re: Investment Opportunities
To:
David Carte
…to risk and return, to provide
OvationBio
the capital it needs to do its early work. Somehow
OvationBio
is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the biggest medical problems in the world—hospital based infections, i.e. MRSA. In addition,
OvationBio
' s technology could produce human enzymes, in modified chickens, on a super cost effective basis.
OvationBio
needs to do proof of concept studies, and develop its…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02082357.pdf
EFTA00351821
Dataset 9
2015-03-06
2p
790w
Subject:
Fwd: Investment Opportunities-David Carter
From:
"David Carter" <
To:
Jeffrey Epstein
…to risk and return, to provide
OvationBio
the capital it needs to do its early work. Somehow
OvationBio
is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the biggest medical problems in the world—hospital based infections, i.e. MRSA. In addition,
OvationBio
' s technology could produce human enzymes, in modified chickens, on a super cost effective basis.
OvationBio
needs to do proof of concept studies, and develop its…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00351821.pdf
EFTA00351818
Dataset 9
2015-03-06
3p
768w
Subject:
FW: Investment Opportunities
From:
"David Carter"
To:
ben carter
…to risk and return, to provide
OvationBio
the capital it needs to do its early work. Somehow
OvationBio
is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the biggest medical problems in the world—hospital based infections, i.e. MRSA. In addition,
OvationBio
' s technology could produce human enzymes, in modified chickens, on a super cost effective basis.
OvationBio
needs to do proof of concept studies, and develop its…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00351818.pdf
EFTA00351823
Dataset 9
2015-03-06
2p
784w
Subject:
Re: Investment Opportunities
From:
Lesley Groff <1
To:
David Carter c4
…to risk and return, to provide
OvationBio
the capital it needs to do its early work. Somehow
OvationBio
is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the biggest medical problems in the world—hospital based infections, i.e. MRSA. In addition,
OvationBio
' s technology could produce human enzymes, in modified chickens, on a super cost effective basis.
OvationBio
needs to do proof of concept studies, and develop its…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00351823.pdf
EFTA00359717
Dataset 9
2014-10-29
2p
364w
Subject:
FW: Confidential
From:
"James Meiskin"
…and rest of the world markets. Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00359717.pdf
EFTA02092616
Dataset 10
2014-10-29
2p
387w
Subject:
Re: Confidential
…Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capital that thinks this is…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02092616.pdf
EFTA02716504
Dataset 11
2014-10-29
2p
397w
Subject:
James Meisken/David Carter
From:
Lesley Groff
To:
Jeffrey Epstein
…and rest =f the world markets. Basically, we get the rights that are =aluable to us at "half price". Over the =ext several years our plan is to identify seven/eight technologies that =re worthy of development. RVC has already agreed to finance the =irst (MAJI) and is looking at the next two —Prediction Biosciences, =nd
OvationBio
. I have several more currently in diligence. =The original Investor Presentation made in Moscow is =ttached) So, I am =ooking for a source…
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02716504.pdf
EFTA00369258
Dataset 9
2014-05-21
2p
511w
Subject:
Re: Confidential
From:
"Jeffrey E." <
[email protected]
>
To:
Lesley Groff
…Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MAI') and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capital that thinks this is…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00369258.pdf
EFTA00631319
Dataset 9
2014-10-30
2p
415w
Subject:
Reminder: James Meisken and David carter
From:
"James Meiskin" eza
To:
Jeffrey Epstein CC <
[email protected]
>
…Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capital that thinks this is…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00631319.pdf
EFTA01201757
Dataset 9
2014-10-29
2p
388w
Subject:
James MeiskenJDavid Carter
From:
"James Meiskin" <
To:
Jeffrey Epstein <
[email protected]
>
…Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capital that thinks this is…
https://www.justice.gov/epstein/files/DataSet%209/EFTA01201757.pdf
EFTA02103110
Dataset 10
2014-05-29
5p
742w
From:
James Meiskin
…Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The EFTA_R1_00713587 EFTA02103113 original Investor Presentation made in Moscow is attached) So, I am looking for a source of capital…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02103110.pdf
EFTA02100345
Dataset 10
2014-05-21
5p
620w
…Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capital that thinks this is…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02100345.pdf
EFTA02105977
Dataset 10
2014-05-21
3p
506w
Subject:
Re: Confidential
From:
ames els an
…Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capital that thinks this is…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02105977.pdf
EFTA02105429
Dataset 10
2014-05-21
2p
468w
…Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capital that thinks this is…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02105429.pdf
EFTA02104933
Dataset 10
2014-05-21
4p
575w
To:
James Meiskini
…Basically, we get the rights that are valuable to us at "half price". Over the next several years our plan is to identify seven/eight technologies that are worthy of development. RVC has already agreed to finance the first (MAJI) and is looking at the next two—Prediction Biosciences, and
OvationBio
. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, lam looking for a source of capital that thinks this is an…
https://www.justice.gov/epstein/files/DataSet%2010/EFTA02104933.pdf
1–20 of 45 results · page 1 of 3
«
←
1
2
3
→
»
Results by Dataset
45 total
Set 9
24
Set 10
19
Set 11
2